Analysts expect BeOne Medicines (formerly BeiGene) to report Q1 2026 revenue of $1.45 billion and earnings per share of $0.85, with the stock currently trading at $293.86 against an average analyst price target of $328.50.
The primary focus for investors is the continued global sales momentum of Brukinsa, which recently surpassed AstraZeneca’s Calquence in quarterly market share for blood cancer treatments.
The company’s strategic rebrand and move to Switzerland reflect a pivot toward global hematology dominance and GAAP profitability. Investors are also closely monitoring the rapid uptake of Tevimbra and the clinical progress of the BGB-16673 pipeline asset as critical long-term catalysts.